nafronyl has been researched along with Diabetic Retinopathy in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klein, M | 1 |
| Hirche, H | 1 |
1 trial available for nafronyl and Diabetic Retinopathy
| Article | Year |
|---|---|
[Naftidrofuryl in the treatment of simple diabetic retinopathy. A double-blind study].
Topics: Aged; Clinical Trials as Topic; Diabetic Retinopathy; Double-Blind Method; Female; Fluorescein Angio | 1985 |